Comparative efficacy Noliprel forte and Ko-renitec at high risk arterial hypertension patients

The aim of the study was to compare i he clinical efficacy and tolerance of fixed combinations of angiotensin-converting enzyme (ACE) and diuretic noliprel and co-renitec in patients with mild and moderate arterial hypertension with high risk of cardiovascular events. All investigated patients didn't achieved normal AP level with monotherapy. The study was blinded, randomised and performed in parallel groups (20 subjects in each group). The clinical effects were evaluated after 6 months of therapy by 1 tablet of noliprel-forte (4 mg / 12.5 mg) or co-renitec (20 mg / 12.5 mg). The antihypertensive effect was comparable for both dings, but fixed combination of noliprel-forte show advantage in reducing of LV hypertrophy and improvement of arterial elasticity.